China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
Baxter International stock has reached a new 52-week low, with shares trading at 18.95 USD. Over the past year, the company's stock has experienced a significant decline, with a 1-year change of -37.2%. Despite this performance, InvestingPro analysis indicates the stock is currently undervalued compared to its Fair Value, potentially offering an opportunity for value investors.This drop reflects broader challenges within the healthcare sector and specific pressures faced by the company, including market conditions and competitive dynamics. While Baxter wasn't profitable over the last twelve months, analysts predict a return to profitability this year with a forecasted EPS of 2.45 USD. The company maintains a GOOD overall financial health rating and has maintained dividend payments for 55 consecutive years, currently offering a 3.03% yield. The new low underscores the ongoing volatility and investor concerns surrounding Baxter International's financial performance and strategic direction.Discover deeper insights with InvestingPro, which offers 7 additional ProTips and a comprehensive Pro Research Report on Baxter, one of 1,400+ US equities covered in-depth.
In other recent news, Baxter International Inc. reported its earnings for the second quarter of 2025, which fell short of expectations. The company posted earnings per share of $0.59, missing the forecasted $0.61, and reported revenue of $2.81 billion, slightly below the anticipated $2.82 billion. Additionally, Baxter announced the resignation of Heather Knight, its Executive Vice President and Chief Operating Officer, effective October 29, 2025. Following her departure, CEO Andrew Hider will assume the interim role of group president of Medical Products and Therapies. In other developments, Baxter received a Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative for its supply chain practices in specific product categories. Furthermore, Baxter, along with other medical device manufacturers, is facing scrutiny after the U.S. Commerce Department launched a national security investigation into medical equipment and devices. This investigation has been described as a new challenge for the medical device sector by Needham.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.